Beam Therapeutics Inc. (BEAM): who owns it and who trades it
As of Nov 16, 2026, BEAM insiders reported 31 open-market sales worth $19.7M and no purchases in the last 12 months, with 6% of the sale value made under pre-set 10b5-1 plans. The largest seller was Fmr Llc (10% owner), with $10M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Beam Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns BEAM
277 funds and institutions reported BEAM shares worth $3.9B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 12.3%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 12.61M | 12.26% | $433M | +1% |
| Farallon Capital Management, L.l.c. | 10.24M | 9.95% | $351M | +1% |
| ARK Investment Management LLC | 10.23M | 9.95% | $351M | -16% |
| BlackRock, Inc. | 9.00M | 8.75% | $309M | +6% |
| State Street Corp | 5.83M | 5.66% | $200M | +2% |
| Vanguard Portfolio Management LLC | 4.92M | 4.78% | $169M | +8% |
| Vanguard Capital Management LLC | 4.60M | 4.47% | $158M | +5% |
| ARCH Venture Management, LLC | 4.54M | 4.41% | $156M | No change |
| California State Teachers Retirement System | 3.59M | 3.49% | $105M | +3229% |
| Amova Asset Management Americas, Inc. | 3.46M | 3.36% | $119M | -10% |
| Sumitomo Mitsui Trust Group, Inc. | 3.46M | 3.36% | $119M | -10% |
| T. Rowe Price Associates | 3.42M | 3.32% | $117M | +26% |
| Kynam Capital Management, LP | 2.84M | 2.76% | $97.5M | -23% |
| Geode Capital Management, LLC | 2.60M | 2.52% | $89.1M | +7% |
| Dimensional Fund Advisors LP | 2.23M | 2.16% | $76.4M | +3% |
| Morgan Stanley | 1.95M | 1.90% | $67M | +201% |
| Contrarius Group Holdings Ltd | 1.61M | 1.57% | $55.4M | +203% |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.55M | 1.51% | $53.3M | -6% |
| Two Sigma Investments, LP | 1.39M | 1.35% | $47.6M | +15% |
| Casdin Capital, LLC | 1.35M | 1.31% | $46.3M | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, BEAM insiders reported $0 of open-market purchases and $19.7M of sales. 6% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 16, 2026 | John M. Evans | CEO | Sale plan | 25,000 | $23.98 | $600K | Form 4 |
| Oct 15, 2026 | John M. Evans | CEO | Sale plan | 25,000 | $23.57 | $589K | Form 4 |
| Oct 1, 2026 | Bethany J Cavanagh | Vice president | Sale plan | 187 | $24.41 | $4.6K | Form 4 |
| Jul 27, 2026 | Amy Simon | Chief Medical Officer | Sale | 16,667 | $25.74 | $429K | Form 4 |
| Jun 30, 2026 | Amy Simon | Chief Medical Officer | Sale | 373 | $34.73 | $13K | Form 4 |
| Jun 30, 2026 | John M. Evans | CEO | Sale | 23,100 | $34.26 | $791K | Form 4 |
| Jun 30, 2026 | John M. Evans | CEO | Sale | 1,900 | $34.84 | $66.2K | Form 4 |
| Jun 29, 2026 | John M. Evans | CEO | Sale | 11,579 | $35.91 | $416K | Form 4 |
| Jun 29, 2026 | John M. Evans | CEO | Sale | 13,421 | $35.13 | $471K | Form 4 |
| Jun 26, 2026 | Fmr Llc | 10% owner | Sale | 251,488 | $35.26 | $8.9M | Form 4 |
| Jun 25, 2026 | Fmr Llc | 10% owner | Sale | 33,372 | $35.12 | $1.2M | Form 4 |
| Apr 1, 2026 | John M. Evans | CEO | Sale | 30,078 | $24.58 | $739K | Form 4 |
| Apr 1, 2026 | Amy Simon | Chief Medical Officer | Sale | 6,700 | $24.58 | $165K | Form 4 |
| Apr 1, 2026 | Bethany J Cavanagh | Vice president | Sale | 3,242 | $24.58 | $79.7K | Form 4 |
| Apr 1, 2026 | Christine Bellon | Chief Legal Officer | Sale | 5,956 | $24.58 | $146K | Form 4 |
| Apr 1, 2026 | Giuseppe Ciaramella | President | Sale | 11,810 | $24.58 | $290K | Form 4 |
| Mar 31, 2026 | John M. Evans | CEO | Sale | 25,000 | $22.76 | $569K | Form 4 |
| Mar 30, 2026 | John M. Evans | CEO | Sale | 25,000 | $22.37 | $559K | Form 4 |
| Feb 24, 2026 | Giuseppe Ciaramella | President | Sale | 35,000 | $32.00 | $1.1M | Form 4 |
| Jan 30, 2026 | John M. Evans | CEO | Sale | 2,906 | $29.00 | $84.3K | Form 4 |
| Jan 30, 2026 | John M. Evans | CEO | Sale | 22,094 | $28.27 | $625K | Form 4 |
| Jan 29, 2026 | John M. Evans | CEO | Sale | 16,333 | $29.19 | $477K | Form 4 |
| Jan 29, 2026 | John M. Evans | CEO | Sale | 8,667 | $29.74 | $258K | Form 4 |
| Jan 22, 2026 | Bethany J Cavanagh | Vice president | Sale | 6,198 | $35.00 | $217K | Form 4 |
| Jan 22, 2026 | Christine Bellon | Chief Legal Officer | Sale | 1,371 | $34.00 | $46.6K | Form 4 |
| Jan 20, 2026 | Bethany J Cavanagh | Vice president | Sale | 3,034 | $30.12 | $91.4K | Form 4 |
| Jan 15, 2026 | Christine Bellon | Chief Legal Officer | Sale | 15,959 | $34.72 | $554K | Form 4 |
| Jan 15, 2026 | Christine Bellon | Chief Legal Officer | Sale | 2,111 | $33.62 | $71K | Form 4 |
| Jan 15, 2026 | Christine Bellon | Chief Legal Officer | Sale | 559 | $35.40 | $19.8K | Form 4 |
| Dec 31, 2025 | Sravan Kumar Emany | CFO | Sale | 6,294 | $27.10 | $171K | Form 4 |
| Dec 31, 2025 | Christine Bellon | Chief Legal Officer | Sale | 1,254 | $27.10 | $34K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Fmr Llc | 10% owner | – | $10M | Jun 26, 2026 |
| John M. Evans | CEO, Director | – | $6.2M | Oct 16, 2026 |
| Giuseppe Ciaramella | President | – | $1.4M | Apr 1, 2026 |
| Christine Bellon | Chief Legal Officer | – | $872K | Apr 1, 2026 |
| Amy Simon | Chief Medical Officer | – | $607K | Jul 27, 2026 |
| Bethany J Cavanagh | SVP, Finance and Treasurer | – | $393K | Oct 1, 2026 |
| Sravan Kumar Emany | Chief Financial Officer | – | $171K | Dec 31, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
BEAM short interest
Very high short interest. 25.2% of BEAM shares are sold short: about 1 share in 4. Over the last 12 reports the number of shares short went down 2%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 26.08M BEAM shares were sold short, 25.2% of the shares outstanding, down 0.6% from the report before. At the average daily volume of 1.90M shares, buying them all back would take about 13.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 26.08M | 25.20% | -1% | 1.90M | 13.7 |
| Oct 15, 2026 | 26.24M | 25.41% | -5% | 1.86M | 14.1 |
| Sep 30, 2026 | 27.55M | 26.67% | +6% | 1.80M | 15.3 |
| Sep 15, 2026 | 25.88M | 25.06% | +0% | 2.06M | 12.6 |
| Aug 31, 2026 | 25.80M | 24.98% | +6% | 1.74M | 14.8 |
| Aug 14, 2026 | 24.37M | 23.60% | +4% | 1.52M | 16.1 |
| Jul 31, 2026 | 23.50M | 22.75% | +1% | 2.08M | 11.3 |
| Jul 15, 2026 | 23.22M | 22.57% | +1% | 2.60M | 8.9 |
| Jun 30, 2026 | 22.88M | 22.24% | -19% | 2.73M | 8.4 |
| Jun 15, 2026 | 28.31M | 27.52% | +32% | 1.99M | 14.2 |
| May 29, 2026 | 21.46M | 20.86% | -19% | 1.83M | 11.7 |
| May 15, 2026 | 26.52M | 25.77% | +27% | 2.11M | 12.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Beam Therapeutics company events
Beam Therapeutics filed 10 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 3, 2026.
- Nov 3, 2026ResultsReleased financial results. Filing
- Aug 4, 2026ResultsReleased financial results. Filing
- Jun 8, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 5, 2026AgreementEnded an important agreement. Filing
- Feb 24, 2026AgreementBeam Therapeutics Inc. entered into a financing agreement with certain subsidiaries of the Company as guarantors party thereto, the lenders party thereto, and Sixth Street Lending Partners, as the administrative agent and collateral agent for the Lenders. Filing
- Feb 12, 2026AgreementAs previously reported, Beam Therapeutics Inc. and Bio Palette Co., Ltd. are parties to a License Agreement dated March 27, 2019, pursuant to which the Company has sublicensed from Bio Palette certain patents that Bio Palette licensed directly from Kobe University under a License Agreement dated… Filing
- Feb 5, 2026LeadershipCarole Ho provided Beam Therapeutics Inc. with notice of her resignation from the Board of Directors of the Company, effective as of February 27, 2026. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Dec 11, 2025DealBristol-Myers Squibb Company completed its previously announced acquisition of Orbital Therapeutics, Inc. pursuant to an Agreement and Plan of Merger dated October 10, 2025 between Orbital and BMS. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Beam Therapeutics financials
Famous investors that hold BEAM
4 of the 50 well-known investors we track reported holding BEAM in their latest 13F filing. The largest position is Cathie Wood's, worth $289M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Cathie Wood · ARK Investment Management | Q3 2026 | 11.81M | $289M | 1.7% | +15% |
| Stanley Druckenmiller · Duquesne Family Office | Q3 2026 | 699,700 | $17.1M | 0.4% | +356% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 56,453 | $1.4M | 0.0% | +15% |
| Israel Englander · Millennium Management | Q3 2026 | 22,725 | $556K | 0.0% | -34% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named BEAM in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | ARK Investment Management LLC | 13G/A | 11.4% |
| Nov 13, 2026 | ARK Investment Management LLC | 13G/A | 11.4% |
Questions about Beam Therapeutics Inc. (BEAM) stock
Who owns the most BEAM stock?
The largest reported owner of Beam Therapeutics Inc. (BEAM) is FMR LLC (Fidelity), with 12.3% of the company. In total, 277 funds and institutions reported holding BEAM at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are BEAM insiders buying or selling?
In the last 12 months, BEAM insiders reported no open-market purchases and 31 sales worth $19.7M. The latest trade was on Oct 16, 2026. See every trade.
What is the short interest in BEAM?
As of Oct 30, 2026, 26.08M BEAM shares were sold short, 25.2% of the shares outstanding, down 0.6% from the report before. At the average daily volume of 1.90M shares, buying them all back would take about 13.7 trading days (days to cover). See the history.
Which famous investors hold BEAM?
4 of the 50 well-known investors we track reported BEAM in their latest 13F filing, including Cathie Wood, Stanley Druckenmiller, Paul Tudor Jones. The largest position is worth $289M. See all holders.
Executive pay
Beam Therapeutics's chief executive was paid a total of $5.8M for the year ended Dec 31, 2025, down 9% from $6.4M the year before. In the last 12 months, Beam Therapeutics's executives and directors bought no stock on the open market and sold $9.7M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.